LEXX vs. IMRX, IMUX, ZIVO, XCUR, MGX, IRD, ANL, PDSB, CTOR, and ASRT
Should you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Immuneering (IMRX), Immunic (IMUX), ZIVO Bioscience (ZIVO), Exicure (XCUR), Metagenomi (MGX), Opus Genetics (IRD), Adlai Nortye (ANL), PDS Biotechnology (PDSB), Citius Oncology (CTOR), and Assertio (ASRT). These companies are all part of the "pharmaceutical products" industry.
Lexaria Bioscience vs. Its Competitors
Immuneering (NASDAQ:IMRX) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, community ranking, dividends, analyst recommendations, profitability, earnings and valuation.
In the previous week, Immuneering had 2 more articles in the media than Lexaria Bioscience. MarketBeat recorded 4 mentions for Immuneering and 2 mentions for Lexaria Bioscience. Immuneering's average media sentiment score of 0.82 beat Lexaria Bioscience's score of 0.47 indicating that Immuneering is being referred to more favorably in the media.
Immuneering has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.
67.7% of Immuneering shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 25.0% of Immuneering shares are held by company insiders. Comparatively, 26.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Lexaria Bioscience has higher revenue and earnings than Immuneering. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.
Immuneering presently has a consensus price target of $14.33, suggesting a potential upside of 576.10%. Lexaria Bioscience has a consensus price target of $7.00, suggesting a potential upside of 573.08%. Given Immuneering's higher probable upside, equities analysts plainly believe Immuneering is more favorable than Lexaria Bioscience.
Immuneering received 32 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 70.91% of users gave Immuneering an outperform vote.
Immuneering has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,473.04%. Immuneering's return on equity of -79.19% beat Lexaria Bioscience's return on equity.
Summary
Immuneering beats Lexaria Bioscience on 11 of the 18 factors compared between the two stocks.
Get Lexaria Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexaria Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:LEXX) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy LEXX Stock Free LEXX Stock Alerts